Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of GSK134612 versus Mencevax ACWY in adolescents
2012-000282-20Phase 3
- Sponsor
- GSK
- Start
- Apr 2012
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in meningococcal disease comparing GSK134612 intramuscular with Mencevax ACWY subcutaneous (2 arms). Primary endpoint: Vaccine response to meningococcal antigens.
02
Drugs
meningococcal conjugate vaccine GSK 134612meningococcal ACYW135 vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2012-000282-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000282-20.